prgn-3006
pgen therapeutics
['leukemia', 'prgn-3006', 'myeloid']
counting down to #ash22! data from phase 1/1b safety study of prgn-3006 ultracar-t will be presented on mon., dec. 12, from 6-8pm ct. to learn more about the abstract, visit: 
Precigen (Nasdaq: PGEN) is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies.